In conclusion, chronic administration of GH to liraglutide‐treated UCD‐T2DM rats did not further delay the onset of T2DM and did not significantly alter other related metabolic or endocrine outcomes (including pancreatic islet area or insulin content) in this model. The gene discussed is GH1; the disease is type 2 diabetes mellitus.